UNSPSC 51171718: Rolgamidine

This classification denotes an antidiarrheal agent with the molecular formula C9H16N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M3NG13839, chemically known as 1h-pyrrole-1-acetamide, n-(aminoiminomethyl)-2,5-dihydro-2,5-dimethyl-, trans but generally known as rolgamidine, which bears US NIH Compound Identifier 3055175. European Medicines Agency schedules Rolgamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10364MIG.

UNSPSC 51171718 Rolgamidine is a Commodity code under which state and local governments procure laboratory testing services for drug screening and confirmation, particularly within criminal justice, community supervision, and health benefits administration contexts. The recent solicitations show that purchasing bodies acquire immunoassay screening with LC/MS/MS or GC/MS confirmation methodologies, oral fluid and hair testing alternatives, and related specimen collection and chain-of-custody operations, rather than the chemical compound itself. Issuing bodies include county criminal justice agencies (community supervision and corrections departments), state health and human services commissions managing pharmacy benefit programs for employee and beneficiary populations, and multistate cooperative purchasing alliances coordinating procurement across multiple jurisdictions. The scope reflects demand for SAMHSA-, state DPS-, or CAP-certified laboratory services bundled with staffing, electronic result reporting, and Interactive Voice Response systems for randomized testing notifications.

Recent activity is concentrated in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026, seeking approximately 25,031 annual tests across five-panel and six-panel screens with confirmation, estimated contract value $600,000 over two years with three optional one-year renewals, awarded on best evaluated offer considering price and qualifications with Phase 1 and optional Phase 2 scoring components. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement strategy before formal RFP issuance. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities including Oregon, requiring cGMP and DSCSA compliance with authorized wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson.